Advertisement ProCure Centers obtains additional $35 million in financing - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

ProCure Centers obtains additional $35 million in financing

ProCure Treatment Centers has received an additional $35 million round of equity funding from Oklahoma City-based McClendon Venture Company.

The $35 million investment represents the second major investment in ProCure by McClendon Venture Company (MVC) and pushes the firm’s total investment in the growing proton therapy treatment company to $70 million. ProCure received an initial $35 million investment from MVC and several related individuals in December 2006.

ProCure will use the funds to support its ongoing development activities and corporate operations. ProCure’s Training and Development Center simulates all aspects of proton therapy treatment in a replica of a proton therapy treatment center without using actual protons. The Center provides clinical, technical, interpersonal and administrative training for the medical staff who will be involved with delivering the proton therapy treatment at ProCure’s facilities.